pradigastat

 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

AcetatesAminopyridines

Narrower (1)

LCQ908

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Pradigastat disposition in humans: in vivo and in vitro investigations.
1. Pradigastat is a potent and specific diacylglycerol acyltransferase-1 (DGAT1) inhibitor effective in lowering postprandial… (More)
Is this relevant?
2017
2017
A Diacylglycerol Transferase 1 Inhibitor Is a Potent Hepatitis C Antiviral in Vitro but Not in Patients in a Randomized Clinical Trial.
Hepatitis C virus (HCV) infection is a significant cause of liver disease affecting 80-150 million people globally… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2016
2016
Effect of Pradigastat, a Diacylglycerol Acyltransferase 1 Inhibitor, on the QTcF Interval in Humans.
Pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor, has been studied in familial chylomicronemia syndrome. To… (More)
Is this relevant?
2016
2016
Assessment of pharmacokinetic drug-drug interaction between pradigastat and atazanavir or probenecid.
Pradigastat, a novel diacylglycerol acyltransferase-1 inhibitor, has activity in common metabolic diseases associated with… (More)
Is this relevant?
2015
2015
Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome
Familial chylomicronemia syndrome (FCS) is a rare lipid disease caused by complete lipoprotein lipase (LPL) deficiency resulting… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2015
2015
Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects.
Pradigastat is a potent and selective inhibitor of diacylglycerol acyltransferase 1, an enzyme highly expressed in the small… (More)
Is this relevant?
2015
2015
Evaluation of food effect on the oral bioavailability of pradigastat, a diacylglycerol acyltransferase 1 inhibitor.
Pradigastat, a diacylglycerol acyltransferase 1 inhibitor, is being developed for the treatment of familial chylomicronemia… (More)
Is this relevant?
2015
2015
Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor.
BACKGROUND AND OBJECTIVE Pradigastat, a diacylglycerol acyltransferase1 inhibitor, is being developed for the treatment of… (More)
Is this relevant?
2015
2015
Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor.
BACKGROUND AND OBJECTIVE Pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor, is under development to treat familial… (More)
  • table 1
  • figure 1
  • figure 2
  • table 3
  • figure 3
Is this relevant?
2014
2014
Pharmacokinetic and pharmacodynamic drug-drug interaction assessment between pradigastat and digoxin or warfarin.
Pradigastat, a novel diacylglycerol acyltransferase-1 inhibitor, was evaluated for both pharmacokinetic (PK) and pharmacodynamic… (More)
Is this relevant?